Related references
Note: Only part of the references are listed.Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions
Xiang Nan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors
Ju Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors
Zhen Wang et al.
BIOORGANIC CHEMISTRY (2020)
Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo [1,5-a] pyrimidine derivatives as potential c-Met inhibitors
Guolin Luo et al.
BIOORGANIC CHEMISTRY (2020)
c-Met kinase inhibitors: an update patent review (2014-2017)
Qing-Wen Zhang et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors
Haoliang Yuan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design, synthesis, and biological evaluation of Cyclobentinib (CB1107) as a potential anti-CML agent
Zijun Zhou et al.
MEDICINAL CHEMISTRY RESEARCH (2018)
Synthesis and biological evaluation of novel 6,11-dihydro-5H-benzo[e] pyrimido- [5,4-b][1,4]diazepine derivatives as potential c-Met inhibitors
Daowei Huang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors
Qidong Tang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy
Zhong-Hua Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target
S. Pilotto et al.
CANCER TREATMENT REVIEWS (2017)
Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy) quinoline derivatives as selective c-Met inhibitors
Xiaoqiang Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Design and Synthesis of Novel 4-Phenoxyquinolines Bearing 3-Hydrosulfonylacrylamido or 1H-Imidazole-4-carboxamido Scaffolds as c-Met Kinase Inhibitors
Jiao Wang et al.
ARCHIV DER PHARMAZIE (2017)
Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors
Ju Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models
Yuji Piao et al.
NEURO-ONCOLOGY (2016)
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
Bryan D. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells
Shweta Shrivastava et al.
APOPTOSIS (2014)
MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation
Jin Kyung Rho et al.
CANCER RESEARCH (2014)
Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors
Lei Ding et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
Yu Kataoka et al.
INVESTIGATIONAL NEW DRUGS (2012)
Structure-Based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based Derivatives
Mark H. Norman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro
Yao Dai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
Fawn Qian et al.
CANCER RESEARCH (2009)
Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
Gretchen M. Schroeder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Molecular markers distinguish bone marrow mesenchymal stem cells from fibroblasts
M Ishii et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Share Paper
